There have been rare and unexpected reports from outside the UK of thromboembolic events such as stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism in association with Vivaglobin use.

Investigations revealed pro-coagulant activity of some batches. The affected batches are no longer being distributed by the manufacturer (although some may still be in use), and only batches with low pro-coagulant activity will be distributed in future. A supply shortage is not envisaged and alternative treatments are available.

Advice for healthcare professionals:

where possible, use an appropriate alternative therapy for patients at increased risk of thrombosis

vivaglobin is not indicated for intravenous use. Do not infuse Vivaglobin intravenously and make sure that no vessel is damaged during subcutaneous injection

be extra vigilant for signs of a thromboembolic event in patients who receive Vivaglobin, particularly if they have pre-existing risk factors

patients should be advised to seek immediate medical attention if first symptoms of a thromboembolic event occur, such as shortness of breath, pain and swelling of a limb, focal neurological deficits, chest pain, or other manifestations

report any suspected adverse reactions with Vivaglobin through the Yellow Card Scheme at www.yellowcard.gov.uk

Help us improve GOV.UK

Help us improve GOV.UK

To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.